Our investment group is encouraged by ENTA’s Phase 2 RSV results. As Dew noted, the overall dataset appears robust and the presentation was clear. We would value your perspectives on the prospects for a partnership and the drug’s continued development. Thank you all for your time and insights.
Market Data 
Markets 
AI
